The Role of Selective Serotonin Reuptake Inhibitors in Reducing Alcohol Consumption
Total Page:16
File Type:pdf, Size:1020Kb
Naranjo and Knoke The Role of Selective Serotonin Reuptake Inhibitors in Reducing Alcohol Consumption Claudio A. Naranjo, M.D., and Della M. Knoke, M.A. © CopyrightPreclinical and clinical 2001 studies Physicians demonstrated an inverse Postgraduate relationship between serotonergic Press, activity Inc. and alcohol consumption. The selective serotonin reuptake inhibitors (SSRIs) fluoxetine, citalopram, and fluvoxamine have subsequently been examined for their ability to reduce alcohol consumption in alcoholic subjects. Interindividual variability in response to SSRIs is large, with reductions in alcohol consumption ranging from 10% to more than 70%. Several factors, including gender, alcoholic sub- type, and extent of drinking, appear to affect the treatment efficacy of the SSRIs. A significant chal- lenge for researchers is to identify the subject variables that predict treatment response, providing a basis for guiding alcohol-dependent individuals to the treatment that is most likely to be effective for them. This article reviews the available clinical studies, discusses possible mechanisms of action for the SSRIs, and describes a model for predicting treatment responses in alcoholic subjects. (J Clin Psychiatry 2001;62[suppl 20]:18–25) One personal copy may be printed he development of substance use disorders results Serotonin plays an important role in several aspects of ad- T from the interaction of drugs of abuse with multiple diction, including reward, craving, and relapse. neurochemical substrates within a social and cultural con- text. Although the present article focuses on the role of se- STUDIES IN ANIMALS rotonin, various neurotransmitter and receptor systems have been associated with drug reward and the patho- Several inbred strains of alcohol-preferring animals physiology of substance use disorders.1 Substantial evi- have been selected from heterogeneous populations and dence supports the role of direct or indirect stimulation of examined as animal models of genetic predisposition for dopaminergic neurotransmission as a fundamental prop- alcohol preference. Reduced levels of serotonin (5-HT) erty of drugs of abuse, including cocaine, opioids, nico- and its metabolite 5-hydroxyindoleacetic acid (5-HIAA) tine, and ethanol in both animals and humans.2–4 In addi- have been found in alcohol-preferring mice and rats (e.g., tion, drug reward is also mediated by the opioid system AA rats and C57BL6J mice) before ethanol exposure and (including the amygdala, locus ceruleus, and periaque- after washout, suggesting reduced serotonin synthesis (for ductal gray area) and the γ-aminobutyric acid system in- reviews, see LeMarquand et al.5 and Li and McBride6). corporating the cortex, cerebellum, hippocampus, and These results suggest an inverse relationship between se- nucleus accumbens. Other neural systems such as acetyl- rotonin concentrations and alcohol preference. choline and various other neuropeptides may also have In the 1980s, several selective serotonin reuptake in- roles in the pathophysiology of substance use disorders. hibitors (SSRIs) became available, mostly as novel anti- depressants in various stages of development. SSRIs block the serotonin uptake pump, enhancing serotonin neuro- transmission. Therefore, these agents provided an oppor- tunity to examine the impact on alcohol consumption of From the Departments of Pharmacology, Psychiatry, increasing serotonergic neurotransmission (for a review, and Medicine, University of Toronto, Psychopharmacology see Naranjo and Bremner7). Preference paradigms were Research Program, Sunnybrook and Women’s College Health Sciences Centre, Sunnybrook Campus, Toronto, Ontario, employed to provide rats the choice of a nonalcoholic Canada. solution or an alcoholic solution. Precision in recording Presented at the closed roundtable symposium “Pharmacological Treatment of Alcohol Abuse and Addiction,” improved with the development of a “drinkometer” (an which was held on February 28, 2000, in Philadelphia, Pa., electronic device for measuring alcohol intake) with a and supported by an unrestricted educational grant from pressure transducer, developed with our biomedical engi- Forest Laboratories, Inc. Reprint requests to: Claudio A. Naranjo, M.D., University of neering colleagues. This drinkometer was connected to a Toronto, Sunnybrook and Women’s College Health Sciences Hewlett-Packard computer, and the data were transcribed Centre, Sunnybrook Campus, Psychopharmacology Research Program, Room F327, 2075 Bayview Ave., Toronto, Ontario, as they were acquired. Research using preference and Canada M4N 3M5. other paradigms consistently reported that a variety of 18 J Clin Psychiatry 2001;62 (suppl 20) SSRIs in Reducing Alcohol Consumption Table 1. Fluoxetine and Alcoholism: Placebo-Controlled Studies provides a direct measurement of Treatment drug effect. Study Type of Drinker (N) Dose Duration Parameters Outcome or dependent mea- Naranjo et al, 199019 Mild to moderate (29) 40 mg/d 4 weeks ∆ drinks/d sures vary from study to study de- ∆ abstinence pending on the treatment goals 60 mg/d 4 weeks ∆ drinks/d ∆ abstinence set. For example, in Canada, mod- Gorelick and Paredes, 199220 Dependent (20) Up to 80 mg/d 4 weeks ∆ drinks/d eration of alcohol intake is an ac- Naranjo et al, 199421 Mild to moderate (16) 60 mg/d 2 weeks ∆ drinks/d ceptable goal in human studies of ∆ abstinence Kranzler et al, 199522 Dependent (101) Up to 60 mg/d 12 weeks ∆ drinks/d mildly to moderately dependent individuals. Abstinence is consid- © Copyright 2001 Physicians Postgraduateered thePress, preferred Inc. goal for indi- SSRIs reduced alcohol consumption by 50% to 70%, viduals who are highly dependent. In the United States, depending on the SSRI dose administered8 (for a review, however, abstinence is the preferred goal for all levels of see LeMarquand et al.5) dependence. Although abstinence is explicitly advised Results of animal studies provided a basis for early and preferred in many studies, drinking during treatment clinical pharmacologic tests. Some difficulties were ap- is often recorded to monitor “slips” (any return to drink- parent in extrapolating from rat to human studies. For ex- ing) and relapses (5 drinks for men or 4 for women in 1 ample, it was difficult to extrapolate from rat studies the sitting).10 SSRI dose required to reduce alcohol consumption in hu- mans. In clinical practice, the desired doses are within the Serotonin Reuptake Inhibitors therapeutic range for antidepressant effect. In addition, and Alcohol Consumption the standards for assessing efficacy Oneoften personaldiffer in animal copy may Correlationalbe printed studies of alcohol-dependent individuals and human studies. Efficacy in animal studies is depen- suggest that brain serotonergic activity is inversely dent on the drug’s ability to reduce alcohol consumption. related to ethanol consumption. Abstinent alcoholics However, in the United States, human studies often seek have been shown to have reduced cerebrospinal fluid to evaluate the drug’s ability to maintain a state of absti- (CSF) 5-HIAA levels,11,12 low platelet 5-HT content,13 nence. Thus, although animal models of alcoholism pro- and low tryptophan availability in plasma,14 suggesting vide a mechanism for screening new drugs, the clinical decreased central serotonergic function. In addition, value of a new medication is ultimately dependent on the although results are mixed, blunted neuroendocrine re- results of human studies. sponses have been documented in detoxified alcoholics administered m-chlorophenylpiperazine,15 MK212,16 and STUDIES IN HUMANS fenfluramine,17,18 suggesting reduced responsivity of the serotonergic system. Protocols assessing the effect of medication on alcohol An inverse relationship between serotonergic activity consumption tend to be similar. At intake, psychosocial and alcohol consumption is also partially supported by tests are administered to assess degree of alcohol depen- studies examining the impact of serotonergic agonists on dence (e.g., the Alcohol Dependence Scale), psychologi- ethanol intake. Although administration of 5-HIAA pre- cal/psychiatric status, and level of function (DSM-IV). cursors had no effect on alcohol intake, several selective In addition, a brief medical assessment, laboratory tests, serotonin reuptake inhibitors have been employed with and a urine screen for drugs of abuse are included to as- some success. Tables 1 through 3 summarize studies ex- sess medical eligibility for participation. Once included in amining the effect of SSRIs on alcohol consumption and the study, subjects monitor on a daily basis alcohol intake, craving. tobacco use, and use of the study medication. Compliance The first SSRIs available for testing were zimelidine can be assessed by adding riboflavin to the study medica- and viqualine. Although research on these agents sug- tion and then measuring the concentration of riboflavin in gested that they reliably reduced alcohol consumption, the urine. During the baseline phase, riboflavin concen- the appearance of significant adverse effects led to a tration in urine is relatively low, followed by a 7- to 12- withdrawal of these agents from the market. Fluoxetine, fold increase when subjects take the medication. Studies fluvoxamine, citalopram, paroxetine, and sertraline were that include a washout period show reductions in ribo- all subsequently introduced. Using the IC50 ratio to mea- flavin during this period, with increases once treatment sure the in vitro competitive inhibition